With the
support of the U.S. Congress, the U.S. government, through the U.S.
Agency for International Development’s (USAID’s) neglected tropical
disease (NTD) Program, has supported countries to deliver more than half a billion NTD treatments in
just six years, reaching cumulatively more than 250 million people in
20 countries. Leveraging unprecedented donations of medicines by
pharmaceutical companies, global neglected tropical disease (NTD)
partnerships are supporting countries around the world to control and
eliminate these diseases.
The United
States today is joining more than 40 nongovernmental organizations,
academic institutions, global health and civil society organizations to
hail historic progress, celebrate champions, and underscore continuing
challenges in the global fight against diseases affecting the world’s
poorest and most marginal populations.
NTDs
are caused by a range of worms, bacteria and parasites with
hard-to-pronounce names such as schistosomiasis, lymphatic filariasis
and onchocerciasis. They disproportionately impact poor and rural
populations who lack access to safe water, adequate sanitation, and
health care. These diseases can kill and frequently impair, blind, or
disfigure those they infect. NTDs devastate families and communities by
hindering children’s mental and physical development, reducing school
performance and attendance, and limiting economic productivity in adults
who become blind or too sick to work, thereby keeping families in a
continuous cycle of poverty. Due to their primary role as caretakers of
children, women are more commonly affected than men, suffering from NTDs
like trachoma which causes pain and blindness during the most
productive years of life. And certain NTDs, like Chagas disease and
sleeping sickness, are potentially fatal without treatment.
“To
date, USAID’s NTD program is the largest public-private partnership
collaboration in our 50 year history,” states Dr. Ariel Pablos-Mendez,
Assistant Administrator for USAID’s Global Health Bureau. “Over the past
six years, USAID has leveraged over $3 billion in donated medicines
reflecting one of the most cost effective public health programs.
Because of this support, we are beginning to document control and
elimination of these diseases in our focus countries and we are on track
to meet the 2020 goals.”
Global
partnerships have been instrumental to the efforts of governments and
others who work together to create new medicines, get the drugs to the
communities that need them, and enlist local support to ensure
appropriateness of proposed interventions. Our work is making a
large-scale, cost-effective contribution to the global effort to reduce
the burden of NTDs.
All
partners are committed to sustaining or expanding existing drug
donation programs; accelerating research and development of new drugs,
vaccines, and diagnostics; and strengthening drug distribution and
implementation programs in disease-endemic countries.
No comments:
Post a Comment